SYCP2 and cancer: Together, our results suggest that aberrant expression of SYCP2 in cancer promotes TC-HR and confers DDR drug resistance, revealing a promising biomarker to predict the resistance to DDR drugs and a potential target overcome in cancer therapy in the future.